Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recombinant adeno-associated virus serotype 2 (rAAV2) empty vector is a viral vector derived from the AAV2 serotype that lacks a therapeutic transgene or genetic payload. In the context of gene therapy development and clinical trials, it is primarily used as a negative control to distinguish the effects of the viral capsid and the host's immune response from the effects of transgene expression. AAV2 is the most well-characterized AAV serotype, known for its ability to infect a wide range of cell types, including neurons, hepatocytes, and muscle cells, by binding to the heparan sulfate proteoglycan (HSPG) receptor and the adeno-associated virus receptor (AAVR). While empty capsids are often considered impurities in therapeutic AAV preparations, they are also studied for their immunological properties and have been investigated as 'decoys' to sequester neutralizing antibodies, potentially enhancing the transduction efficiency of transgene-carrying vectors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on recombinant adeno-associated virus serotype 2 empty vector.